$3.98
2.31% yesterday
Nasdaq, Sep 27, 10:00 pm CET
ISIN
US89532E1091
Symbol
TRVN
Sector
Industry

Trevena, Inc. Stock price

$3.98
-0.61 13.29% 1M
-7.49 65.29% 6M
-14.07 77.95% YTD
-13.02 76.58% 1Y
-808.52 99.51% 3Y
-583.52 99.32% 5Y
-4,102.27 99.90% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
+0.09 2.31%
ISIN
US89532E1091
Symbol
TRVN
Sector
Industry

Key metrics

Market capitalization $3.32m
Enterprise Value $23.42m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 53.23
P/S ratio (TTM) P/S ratio 7.55
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth -82.85%
Revenue (TTM) Revenue $440.00k
EBIT (operating result TTM) EBIT $-35.36m
Free Cash Flow (TTM) Free Cash Flow $-31.54m
Cash position $16.37m
EPS (TTM) EPS $-55.32
P/E forward negative
P/S forward 11.07
EV/Sales forward 78.07
Short interest 2.38%
Show more

Is Trevena, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Trevena, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Trevena, Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Trevena, Inc.:

Buy
100%

Financial data from Trevena, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
0.44 0.44
83% 83%
100%
- Direct Costs 2.14 2.14
42% 42%
486%
-1.70 -1.70
57% 57%
-386%
- Selling and Administrative Expenses 18 18
23% 23%
4,009%
- Research and Development Expense 16 16
6% 6%
3,530%
-35 -35
14% 14%
-7,923%
- Depreciation and Amortization 0.49 0.49
43% 43%
111%
EBIT (Operating Income) EBIT -35 -35
15% 15%
-8,035%
Net Profit -37 -37
3% 3%
-8,411%

In millions USD.

Don't miss a Thing! We will send you all news about Trevena, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Trevena, Inc. Stock News

Neutral
GlobeNewsWire
3 months ago
Trevena expects to receive a non-dilutive $2 million tranche and may be eligible for up to an additional $8 million based on OLINVYK US partnering and commercialization milestones
Neutral
GlobeNewsWire
3 months ago
TRV045 shows potential for sustained, long-term analgesic effect in preclinical model of neuropathic pain, with no evidence of receptor desensitization
Neutral
GlobeNewsWire
5 months ago
TRV045, novel S1P receptor modulator for chronic pain and epilepsy, continues to demonstrate a favorable tolerability profile
More Trevena, Inc. News

Company Profile

Trevena, Inc. engages in the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its product candidates include Oliceridine injection, TRV250, TRV734, and TRV045. The company was founded by Maxine Gowen, Robert Joseph Lefkowitz, Scott DeWire, Howard A. Rockman, Jonathan Violin, and Erin Whalen on November 9, 2007 and is headquartered in Chesterbrook, PA.

Head office United States
CEO Carrie Bourdow
Employees 23
Founded 2007
Website www.trevena.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today